Nassour Ibrahim, Polanco Patricio M
University of Texas Southwestern Medical Center.
VA North Texas Health Care System, Department of Veterans Affairs.
Curr Colorectal Cancer Rep. 2017 Apr;13(2):144-153. doi: 10.1007/s11888-017-0361-x. Epub 2017 Apr 8.
Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is a disease with a poor prognosis, often thought to be a terminal illness with no hope except for palliative treatment. New therapeutic modalities combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown favorable outcomes and may provide a significant survival benefit in a selected group of patients. The main rational for CRS is to remove all visible tumor burden to allow for the chemotherapeutic agent (HIPEC) to eradicate any microscopic residual disease. The Amsterdam statement formulated at the 9th International Congress on Peritoneal Surface Malignancies supports the use of CRS with HIPEC as a standard of care for selected patients with small-to-moderate volume PC from CRC. Selecting appropriate patients who would benefit from CRS/ HIPEC is paramount to derive the maximum oncological outcomes while minimizing the risks of postoperative complications and mortality. In this paper, we will review the role for CRS/HIPEC in the management of PC from CRC.
结直肠癌导致的腹膜癌转移（PC）是一种预后较差的疾病，通常被认为是一种绝症，除了姑息治疗外毫无希望。将减瘤手术（CRS）与腹腔内热灌注化疗（HIPEC）相结合的新治疗模式已显示出良好的效果，并且可能为部分选定患者带来显著的生存益处。CRS的主要原理是清除所有可见的肿瘤负荷，以便化疗药物（HIPEC）根除任何微小的残留病灶。在第9届国际腹膜表面恶性肿瘤大会上制定的阿姆斯特丹声明支持将CRS联合HIPEC作为治疗部分中小体积结直肠癌所致PC患者的标准治疗方法。选择能从CRS/HIPEC中获益的合适患者对于在将术后并发症和死亡率风险降至最低的同时获得最大肿瘤学疗效至关重要。在本文中，我们将综述CRS/HIPEC在结直肠癌所致PC治疗中的作用。
